Tag: months

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Today, June 19^th, 2025, Reykjavík Energy (Orkuveita Reykjavíkur) concluded a green bond auction in the green bond classes OR031033 GB, OR280845 GB and OR180255 GB. Total bids amounted to ISK 1,920 million nominal value.

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- (TSX: PIC.A; PIC.PR.A) Premium Income Corporation (the “Fund”) announces results of operations for the six months ended April 30, 2025. Decrease in net assets attributable to holders of Class A shares amounted to $5.7 million or $0.38 per Class A share. Net assets attributable to holders of Class A shares as at April 30, 2025 were $81.2 million or $5.12 per Class A share. Cash distributions of $0.64 per Preferred share and $0.48 per Class A share were paid during the period.

The following decision was adopted at the Extraordinary General Meeting of Shareholders of LITGRID AB (company code 302564383, registered address at Karlo Gustavo Emilio Manerheimo st. 8, LT-05131, Vilnius) which was held on 19 June 2025: